This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Q3 Earnings Top Estimates, Revenues Miss, Stock Dips
by Zacks Equity Research
In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
Thermo Fisher Scientific (TMO) Q3 Earnings Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.57% and 0.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 3 MedTech Stocks Surpass Q3 Earnings Forecasts?
by Urmimala Biswas
Here is a sneak peek into how three MedTech stocks, BSX, TMO and ALGN, are expected to fare in their third-quarter results, slated to be released tomorrow.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Integer (ITGR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should ISRG Stock Be Part of Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Danaher to Benefit From Business Strength Amid Headwinds
by Zacks Equity Research
DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
by Zacks Equity Research
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
by Zacks Equity Research
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Should You Continue to Hold TMO Stock in Your Portfolio?
by Zacks Equity Research
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
by Zacks Equity Research
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
The Zacks Analyst Blog Highlights JPMorgan Chase, Thermo Fisher, Arista Networks, United Homes Group and GSI
by Zacks Equity Research
JPMorgan Chase, Thermo Fisher, Arista Networks, United Homes Group and GSI are included in this Analyst Blog.
Top Research Reports for JPMorgan, Thermo Fisher & Arista Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Thermo Fisher Scientific Inc. (TMO) and Arista Networks, Inc. (ANET), as well as two micro-cap stocks United Homes Group, Inc. (UHG) and GSI Technology, Inc. (GSIT).
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Top Analyst Reports for Apple, NVIDIA & Coca-Cola
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and The Coca-Cola Company (KO), as well as two micro-cap stocks Star Group, L.P. (SGU) and Aware, Inc. (AWRE).
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
by Zacks Equity Research
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma